Magnetic Resonance - Technology Information Portal Welcome to MRI Technology••
Info
  Sheets


Out-
      side
 



 
 'Drug Information' 
SEARCH FOR    
 
  2 3 5 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Result : Searchterm 'Drug Information' found in 0 term [] and 28 definitions []
1 - 5 (of 28)     next
Result Pages : [1 2 3 4 5 6]
Searchterm 'Drug Information' was also found in the following services: 
spacer
News  (2)  Resources  (6)  
 
ABLAVAR™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.
 
ABLAVAR™ (formerly named Vasovist™) is a blood pool agent for magnetic resonance angiography (MRA), which opens new medical imaging possibilities in the evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.
ABLAVAR™ binds reversibly to blood albumin, providing imaging with high spatial resolution up to 1 hour after injection, due to its high relaxivity and to the long lasting increased signal intensity of blood.
As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered.
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or chronic severe renal insufficiency (glomerular filtration rate less than 30 mL/min/1.73m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
See also Cardiovascular Imaging, Adverse Reaction, Molecular Imaging, and MRI Safety.

Drug Information and Specification
NAME OF COMPOUND Diphenylcyclohexyl phosphodiester-Gd-DTPA, gadofosveset trisodium, MS-325
DEVELOPER EPIX Pharmaceuticals, Inc.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, predominantly positive enhancement
RELAXIVITY 20-45 mmol-1sec-1, Bo=0,47T
PHARMACOKINETIC Intravascular
OSMOLALITY 825 mOsmol/kg H2O
CONCENTRATION 244 mg/mL, 0.25mmol/mL
DOSAGE 0.12 mL/kg, 0.03 mmol/kg
PREPARATION ready to use
INDICATION Contrast enhanced magnetic resonance angiography
DEVELOPMENT STAGE FDA approved
DISTRIBUTOR See below
PRESENTATION 10 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Vasovist™ Approved ?
USA, Canada, Australia ABLAVAR™ Approved Lantheus Medical Imaging, Inc.

spacer
 
• Share the entry 'ABLAVAR™':  Facebook  Twitter  LinkedIn  

• View the NEWS results for 'ABLAVAR™' (1).Open this link in a new window.
 
Further Reading:
  Basics:
Ablavar Prescribing Information
   by www.ablavar.com    
  News & More:
The first FDA-approved blood-pool MR agent offers additional time for imaging and possibly some new applications
Thursday, 1 July 2010   by www.radiologytoday.net    
MRI Resources 
Diffusion Weighted Imaging - Stimulator pool - Spectroscopy pool - Shielding - Breast MRI -
 
Abdoscan®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
This superparamagnetic oral contrast agent consists of large iron oxide particles, coated with insoluble material. Abdoscan® particles have a mean diameter no less than 300 nm. Gastrointestinal superparamagnetic contrast agents are used for negative bowel enhancement.

Abdoscan® was approved in Europe but was taken off the market in 2000, and all sales stopped by the end of 2002.
Drug Information and Specification
NAME OF COMPOUND Ferristene (USAN) oral magnetic particles (OMP)
DEVELOPER Amersham
CENTRAL MOIETY Fe2+/Fe3+
CONTRAST EFFECT T2*, predominantly negative enhancement
RELAXIVITY T2
PHARMACOKINETIC Gastrointestinal
CONCENTRATION 23.4 Fe/200ml
PREPARATION Dissolve
INDICATION Bowel marking
DEVELOPMENT STAGE Not FDA approved
PRESENTATION Bags with powder
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT
spacer

• View the DATABASE results for 'Abdoscan®' (2).Open this link in a new window

MRI Resources 
Supplies - Colonography - Homepages - Cochlear Implant - Knee MRI - DICOM
 
Artirem®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Artirem®, the arthrography-specific contrast agent for MRI is a dilute form of Dotarem® with a less concentration of Gd (1:200). Artirem® has to be injected directly into the joints for better visualization and delimitation, of the ligament and tendon structures in particular.

Drug Information and Specification
NAME OF COMPOUND Gadoterate meglumine, Gd-DOTA
DEVELOPER Guerbet S.A.
CENTRAL MOIETY Gd2+
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY r1=3.4, r2=4.8, B0=1.0T
PHARMACOKINETIC Intravascular, extracellular, renal excretion
CONCENTRATION 0,0025 mmol/ml
PREPARATION Finished product
INDICATION Arthrography
DEVELOPMENT STAGE For sale
DISTRIBUTOR See below
PRESENTATION Pre-filled syringes of 20 mL
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT

Distribution Information
TERRITORY TRADE NAME DEVELOPMENT
STAGE
DISTRIBUTOR
EU Dotarem® for sale Guerbet S.A.
France, Switzerland Artirem® for sale Guerbet S.A.
Australia Dotarem® for sale

spacer

• View the DATABASE results for 'Artirem®' (4).Open this link in a new window

 
Further Reading:
  News & More:
EMA's final opinion confirms restrictions on use of linear gadolinium agents in body scans
Friday, 21 July 2017   by www.ema.europa.eu    
Searchterm 'Drug Information' was also found in the following services: 
spacer
News  (2)  Resources  (6)  
 
Clariscan™InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Clariscan™ (gadoteric acid), a macrocyclic and ionic gadolinium-based contrast agent has newly been approved using the decentralized procedure with marketing authorization in place in Norway. It will be introduced by GE Healthcare to European countries in 2017.


See also: Paramagnetic Contrast Agents, Contrast Medium, Extracellular Fluid Agents, Ionic Intravenous Contrast Agents, Nonionic Intravenous Contrast Agents, Chelate, Adverse Reaction and Nephrogenic Systemic Fibrosis.

See also the related poll result: 'The development of contrast agents in MRI is'

Drug Information and Specification
NAME OF COMPOUND Gadoteric Acid
DEVELOPER GE Healthcare
CENTRAL MOIETY Gadolinium
CONTRAST EFFECT T1, Predominantly positive enhancement
RELAXIVITY R1 3.1, R2 3.6, B0 = 1.5 Tesla
PHARMACOKINETIC Intravascular, extracellular, renal excretion
OSMOLALITY 1350 mOsm.kg-1
CONCENTRATION 0.5 mmol /mL
DOSAGE 0.1 mmol/kg / 0.2 ml/kg
INDICATION Brain, spine and associated tissues
PRESENTATIONS Glass vial 5, 10, 15, 20 mL
Glass bottle 50, 100 mL
Polypropylene bottles 50, 100 mL
Plastic (Crystal Clear Polymer) pre-filled syringes 10, 15, 20 mL
DEVELOPMENT STAGE Sale starts 2017 in Norway, Sweden, UK. Global launch is planned.
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT


[ Clariscan™ was also the name of an contrast agent under development by Amersham Health around the year 2000 which doesn't reach the market: '(An iron-based contrast agent with large molecular size, which prevents diffusion into body tissues and was developed for MR imaging of the liver (taken up by macrophages), tumor microvasculature and microvessel permeability. The blood half live of the particles with 11-20 nm diameter is 3-4 hours. See also NC100150 Injection and Ultrasmall Superparamagnetic Iron Oxide)'.
The new developed Clariscan™ by GE Healthcare is a totally different contrast agent.]
spacer

• View the DATABASE results for 'Clariscan™' (6).Open this link in a new window

 
Further Reading:
  Basics:
SUMMARY OF PRODUCT CHARACTERISTICS
Wednesday, 22 February 2017   by www.mhra.gov.uk    
  News & More:
GE Healthcare expands MRI contrast media product range in Europe with launch of macrocyclic agent ClariscanTM
Wednesday, 1 March 2017   by www.businesswire.com    
MRI Resources 
Absorption and Emission - Fluorescence - Veterinary MRI - Contrast Agents - Artifacts - Spectroscopy
 
Combidex®InfoSheet: - Contrast Agents - 
Intro, Overview, 
Characteristics, 
Types of, 
etc.MRI Resource Directory:
 - Contrast Agents -
 
Combidex® is the brand name (same as Sinerem®) for an ultrasmall superparamagnetic iron oxide (USPIO) in the development pipeline to detect metastatic disease in lymph nodes. Metastatic lymph nodes show less uptake of this MRI contrast agent, which results in less signal decrease and allows the differentiation of normal lymph nodes from normal-sized, metastatic nodes. Combidex® has also potential to be used as a functional molecular imaging agent.
In March 2005, AMAG Pharmaceuticals Inc received an approvable letter from the U.S. Food and Drug Administration with respect to Combidex subject to certain conditions.
See also Ferumoxtran, Drug Development and Approval Process USA, Molecular Imaging and Classifications, Characteristics, etc.

Drug Information and Specification
NAME OF COMPOUND Ferumoxtran, USPIO, AMI-227
DEVELOPER AMAG Pharmaceuticals, Inc.
CENTRAL MOIETY Fe3+/Fe2+
CONTRAST EFFECT T1, predominantly T2
RELAXIVITY r1=25, r2=160, B0=0.47T, r1=23.3, r2=48.9, B0=0.47T
PHARMACOKINETIC Vascular, lymph v. hepatocyte (AG-USPIO)
OSMOLALITY
CONCENTRATION
DOSAGE 2.6 mg Fe/kg
PREPARATION Suspend in an isotonic glucose solution
INDICATION Lymph node, (MR angiography vascular, staging of RES-directed liver diseases)
DEVELOPMENT STAGE
DISTRIBUTOR
PRESENTATION
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT


spacer

• View the DATABASE results for 'Combidex®' (6).Open this link in a new window


• View the NEWS results for 'Combidex®' (1).Open this link in a new window.
 
Further Reading:
  Basics:
The demise of Combidex - Sinerem
Wednesday, 24 March 2010   by www.wellsphere.com    
  News & More:
Combidex, MRI, and identification of nodal metastases
Wednesday, 17 June 2009   by prostatecancerinfolink.net    
Superparamagnetic Iron Oxide–enhanced MR Imaging of Head and Neck Lymph Nodes1
MRI Resources 
Raman Spectroscopy - Case Studies - Colonography - MRA - Absorption and Emission - Journals
 
     1 - 5 (of 28)     next
Result Pages : [1 2 3 4 5 6]
 Random Page
 
Share This Page
FacebookTwitterLinkedIn

MR-TIP    
Community   
User
Pass
Forgot your UserID/Password ?  



Your MRI scanner(s) in 5 years should be :
more automated 
much quicker 
quiet 
voice controlled 
iPhone compatible 
as it is right now 

Look
      Ups





MR-TIP.com uses cookies! By browsing MR-TIP.com, you agree to our use of cookies.

Magnetic Resonance - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • US-TIP • The-Medical-Market
Copyright © 2003 - 2018 SoftWays. All rights reserved. [ 18 July 2018]
Terms of Use | Privacy Policy | Advertising
 [last update: 2018-03-08 05:11:00]